Christopher Wallis1, Suneil Khana2, Mohammad Hajiha1, Robert K Nam1, Raj Satkunasivam1. 1. Division of Urology, Department of Surgery; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 2. Division of Medical Oncology; Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Abstract
INTRODUCTION: We sought to determine the effect of the presence of disseminated disease on perioperative outcomes following radical cystectomy for bladder cancer. METHODS: We identified 4108 eligible patients who underwent radical cystectomy for bladder cancer using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database. We matched patients with disseminated cancer at the time of surgery to those without disseminated cancer using propensity scores. The primary outcome of interest was major complications (death, reoperation, cardiac or neurological event). Secondary outcomes included pulmonary, infectious thromboembolic, and bleeding complications, in addition to prolonged length of stay. Generalized estimating equations were used to examine the association between disseminated cancer and the development of complications. RESULTS: Following propensity score matching and adjusting for the type of urinary diversion, radical cystectomy in patients with disseminated disease was associated with a significant increase in major complications (8.6% vs. 4.0%; odds ratio [OR] 2.50; 95% confidence interval [CI] 1.02-6.11; p=0.045). The presence of disseminated disease was associated with an increase in pulmonary complications (5.8% vs. 1.2%; OR 5.17. 95% CI 1.00-26.66. p=0.049), but not infectious complications, venous thromboembolism, bleeding requiring transfusion, and prolonged length of stay (p values 0.07-0.79). CONCLUSIONS: Patients with disseminated cancer undergoing cystectomy are more likely to experience major and pulmonary complications. The strength of these conclusions is limited by sample size, selection bias inherent in observational data, and a lack of specific oncological detail in the database.
INTRODUCTION: We sought to determine the effect of the presence of disseminated disease on perioperative outcomes following radical cystectomy for bladder cancer. METHODS: We identified 4108 eligible patients who underwent radical cystectomy for bladder cancer using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database. We matched patients with disseminated cancer at the time of surgery to those without disseminated cancer using propensity scores. The primary outcome of interest was major complications (death, reoperation, cardiac or neurological event). Secondary outcomes included pulmonary, infectious thromboembolic, and bleeding complications, in addition to prolonged length of stay. Generalized estimating equations were used to examine the association between disseminated cancer and the development of complications. RESULTS: Following propensity score matching and adjusting for the type of urinary diversion, radical cystectomy in patients with disseminated disease was associated with a significant increase in major complications (8.6% vs. 4.0%; odds ratio [OR] 2.50; 95% confidence interval [CI] 1.02-6.11; p=0.045). The presence of disseminated disease was associated with an increase in pulmonary complications (5.8% vs. 1.2%; OR 5.17. 95% CI 1.00-26.66. p=0.049), but not infectious complications, venous thromboembolism, bleeding requiring transfusion, and prolonged length of stay (p values 0.07-0.79). CONCLUSIONS:Patients with disseminated cancer undergoing cystectomy are more likely to experience major and pulmonary complications. The strength of these conclusions is limited by sample size, selection bias inherent in observational data, and a lack of specific oncological detail in the database.
Authors: Colleen G Koch; Liang Li; Eric Hixson; Anne Tang; Shannon Phillips; J Michael Henderson Journal: J Am Coll Surg Date: 2012-03-14 Impact factor: 6.113
Authors: Robert R Cima; Kandace A Lackore; Sharon A Nehring; Stephen D Cassivi; John H Donohue; Claude Deschamps; Monica Vansuch; James M Naessens Journal: Surgery Date: 2011-08-27 Impact factor: 3.982
Authors: Raj Satkunasivam; Andre E Kim; Mihir Desai; Mike M Nguyen; David I Quinn; Leslie Ballas; Juan Pablo Lewinger; Mariana C Stern; Ann S Hamilton; Monish Aron; Inderbir S Gill Journal: J Urol Date: 2015-02-21 Impact factor: 7.450
Authors: Georgios Gakis; Jason Efstathiou; Seth P Lerner; Michael S Cookson; Kirk A Keegan; Khurshid A Guru; William U Shipley; Axel Heidenreich; Mark P Schoenberg; Arthur I Sagaloswky; Mark S Soloway; Arnulf Stenzl Journal: Eur Urol Date: 2012-08-14 Impact factor: 20.096
Authors: Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford Journal: J Urol Date: 2004-03 Impact factor: 7.450
Authors: Thomas Seisen; Maxine Sun; Jeffrey J Leow; Mark A Preston; Alexander P Cole; Francisco Gelpi-Hammerschmidt; Nawar Hanna; Christian P Meyer; Adam S Kibel; Stuart R Lipsitz; Paul L Nguyen; Joaquim Bellmunt; Toni K Choueiri; Quoc-Dien Trinh Journal: J Clin Oncol Date: 2016-10-10 Impact factor: 44.544
Authors: Christopher J D Wallis; Georg Bjarnason; James Byrne; Douglas C Cheung; Azik Hoffman; Girish S Kulkarni; Avery B Nathens; Robert K Nam; Raj Satkunasivam Journal: Urology Date: 2016-06-09 Impact factor: 2.649
Authors: Ryan P Merkow; Thomas E Kmiecik; David J Bentrem; David P Winchester; Andrew K Stewart; Clifford Y Ko; Karl Y Bilimoria Journal: Cancer Date: 2012-11-26 Impact factor: 6.860
Authors: Luke T Lavallée; David Schramm; Kelsey Witiuk; Ranjeeta Mallick; Dean Fergusson; Christopher Morash; Ilias Cagiannos; Rodney H Breau Journal: PLoS One Date: 2014-10-31 Impact factor: 3.240